Janus Henderson Group’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Janus Henderson Group's PTGX Position: Q3 2026 in Review
Janus Henderson Group reduced its Protagonist Therapeutics (PTGX) stake by 26% in Q3 2026, selling an estimated $79.8M and leaving 1,569,992 shares worth $221M. The position accounts for 0.09% of the portfolio, ranked #196.
Janus Henderson Group first reported a position in PTGX in Q4 2021 and has held it in 16 quarters since. The position peaked at $305M in Q1 2026. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Janus Henderson Group held 1,569,992 shares of Protagonist Therapeutics worth $221M as of Q3 2026.
- Janus Henderson Group sold 559,788 Protagonist Therapeutics shares in Q3 2026, an estimated $79.8M.
- Protagonist Therapeutics made up 0.09% of Janus Henderson Group's portfolio in Q3 2026, its #196 holding.
- Janus Henderson Group first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 16 quarters since.
- Janus Henderson Group's Protagonist Therapeutics position peaked at $305M in Q1 2026.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Janus Henderson Group's 13F filing for Q3 2026, filed 16 Nov 2026.